

Perspectives of colorectal cancer screening in Germany 2009

Andreas Sieg, Kilian Friedrich

Andreas Sieg, Kilian Friedrich, Practice of Gastroenterology and University of Heidelberg, Faculty of Medicine, D-69117 Heidelberg, Germany

Author contributions: Sieg A wrote the paper except the chapter on new developments, which was written by Friedrich K; Friedrich K helped with valuable discussion.

Correspondence to: Dr. Andreas Sieg, Professor, MD, Practice of Gastroenterology and University of Heidelberg, Bergheimer Str. 56 a, D-69117 Heidelberg, Germany. dr.andreas.sieg@t-online.de

Telephone: +49-6221-6599931 Fax: +49-6221-6599933

Received: March 10, 2009 Revised: March 26, 2009

Accepted: April 2, 2009

Published online: October 15, 2009

Abstract

Adequate screening methods can decrease colorectal cancer (CRC) mortality. The guaiac test for fecal occult-blood (FOBT) is part of the German CRC Screening Program since 1970 and has evidence level Ia. In randomized multicenter-studies FOBT has an average sensitivity of 24% and decreases CRC mortality up to 30%. Immunological tests for human haemoglobin (iFOBT) show better performance characteristics than guaiac FOBT, with augmented sensitivity and specificity. However, the single tests show wide differences in diagnostic performance and iFOBT is not yet covered by insurance companies although it should replace the guaiac test for CRC screening. Visual colonoscopy, which was introduced to the German National Cancer Screening Program in 2002, is the gold standard for the diagnosis of colorectal neoplasia. From 2003 to 2007 more than 2.8 million examinations have been documented in Germany. The prevalence of adenomas is around 20% and of CRC about 0.7% to 1.0% of the screenings. Seventy percent of the carcinomas detected during screening are in an early stage (UICC I and II). Furthermore, screening colonoscopy is a cost saving procedure with a low complication rate (0.25% overall). Insurance companies save 216€ for each screening colonoscopy mainly by prevention of neoplasia due

to polypectomy. In Germany, virtual colonography by computed tomography (CT) or magnetic resonance imaging still lacks standardization of the hard and software. In experienced centres the sensitivity for CRC and large polyps of CT colonography is comparable to colonoscopy but in meta-analyses the ranking is lower. New technologies like computer-aided colonoscopies with sheath or double balloon techniques are coming up as well as capsule colonoscopy, which sensitivity for large polyps is about 70%. Advised by his physician, the patient can choose his most acceptable examination method from this whole set of screening tools.

© 2009 Baishideng. All rights reserved.

Key words: Screening, colorectal cancer; Prevention; Colonoscopy; Virtual colonoscopy; Fecal occult blood test; Capsule colonoscopy

Peer reviewer: Akira Hokama, MD, PhD, First Department of Internal Medicine, University of the Ryukyus, Okinawa 903-0215, Japan

Sieg A, Friedrich K. Perspectives of colorectal cancer screening in Germany 2009. *World J Gastrointest Endosc* 2009; 1(1): 12-16 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v1/i1/12.htm> DOI: <http://dx.doi.org/10.4253/wjge.v1.i1.12>

INTRODUCTION

With about 71 400 new occurrences, Germany is among the countries with the highest incidence (71/100 000 males and 50/110 000 females) and mortality rates (30 000 annually) of colorectal carcinoma (CRC). Since the CRC emanates over a time span of 10-15 years from a benign precursor (Adenoma), screening offers an immense opportunity to prevent this malignancy. This review is not about primary prevention like pharmaceuticals or modification of the way of life, but solely about the methods of secondary prevention, excluding DNA testing.

FECAL OCCULT BLOOD TEST

The Guaiac-Test for fecal occult blood test (FOBT) was included to the German CRC Screening Program in the 1970's. If used regularly, FOBT has evidence level Ia for reducing CRC mortality of about 30%^[1-4]. FOBT measures peroxidase activity of the haemoglobin. But this reaction is not specific since the peroxidase of herbal or carnal aliments reacts as well. A great disadvantage of FOBT is its low sensitivity for carcinomas or large polyps, which can only be compensated by annual repetition.

IMMUNOLOGICAL FECAL OCCULT BLOOD TEST

Due to the low sensitivity and specificity of the FOBT, immunological tests for human haemoglobin (iFOBT) were developed. Using a monoclonal antibody, iFOBT can specifically identify human haemoglobin without interfering with carnal proteins or herbal peroxidase. Another advantage of iFOBT is the quantitative interpretation of the results, and thus being able to define a cut-off range for standard values depending on the examined population. For CRC iFOBT has a sensitivity of 66%-95%^[5-8], however iFOBT was only obtained on one day. On firsthand comparison, iFOBT showed an increased sensitivity and specificity than FOBT^[6-20] and higher rates of detection for colorectal neoplasia^[9,14,16,20].

Significant differences in the analytical performance among iFOBT methods were found^[15,21]. Careful method validation and selection of a method with appropriate sensitivity and specificity is therefore essential in colorectal cancer screening. Attention has to be paid to the sampling of feces, as haemoglobin is progressively degraded over time and undetectable after 10 d. This can only be avoided if feces are immediately deep frozen or collected in iFOBT collection devices^[22]. Another way to avoid rapid degradation of hemoglobin is to determine the more stable hemoglobin-haptoglobin complex in stool, which was shown to have a higher sensitivity towards adenomas^[23]. Higher costs for immunological tests could be compensated by the increased sensitivity and therefore higher detection rate of colorectal neoplasia^[24]. In Japan, iFOBT analyzed on 2 d is used for the National Cancer Screening Program. In a case-control study the odds-ratio (OR) of patients dying from colorectal cancer was 0.2 for those screened with the iFOBT^[25]. Even a small percentage of little adenomas in men were detected by iFOBT^[26]. Therefore, the immunological test should replace guaiac FOBT.

In two studies tumor pyruvate kinase isoenzyme M2 was shown to have no supplemental value for screening because of a lower sensitivity and specificity^[27,28] compared to iFOBT.

SCREENING-COLONOSCOPY

Germany was the first country to introduce preventative

colonoscopy to the National Cancer Screening Program in 2002. Until then, no direct evidence for a reduction of mortality existed for this method. Yet, sigmoidoscopy studies^[29-31] and case-controlled studies showed indirect evidence for the correctness of this assumption^[32,33]. The first analysis of screening colonoscopy in Germany showed a prevalence of 20% for adenomas, 6.1% for advanced adenomas, and 0.7% for CRC^[34]. These results are consistent with further studies analyzing screening colonoscopy^[8,35-40]; however, one has to account that the study population varies individually. For instance, it is known that the risk for colorectal neoplasia is elevated for men, and it rises with increasing age^[34,41]. It is important to note that the majority of carcinomas (70% total) found during screening colonoscopy are detected at an early stage (UICC I and II). Thus it is understandable that these carcinomas found during screening accompany a considerably better prognosis than carcinomas found during the clarification of symptoms, as a recent study has proven^[42]. An important feature is the safety of a screening method as the examination is performed in healthy adults. Screening colonoscopy in Germany was shown to be a safe method. Perforations occurred in 0.02%-0.03% of the examinations, bleedings in 0.15%-0.17% and cardiovascular events in 0.06%-0.1%^[34,43]. Similarly low rates of adverse effects were shown for outpatient colonoscopy in Germany some years ago^[44]. A limitation of optical colonoscopy is the miss rate for large adenomas from 2.1% to 6%^[45-49]. Poor colonic cleansing^[50] or short withdrawal times^[51] may contribute to the problem.

By detection and endoscopic resection of early stage adenomas, the successive development of cancer can be prevented. This results in a savings of 216 € in Germany for each screening colonoscopy^[52]. One problem of screening colonoscopy in Germany is the low compliance rate. From 2003 to 2007 more than 2.8 million screening colonoscopies were performed. In the age group of 55-74 years, 15.1% of the women and 13.4% of the men were participating within 5 years^[43]. This means that after 10 years, nearly 30% of the population will be examined, a number that may improve. However, screening colonoscopies account for only one third of the total rate of colonoscopies in Germany. A chance for compliance improvement may be the system of invitation, which has recently been introduced in the state of Saarland. A study in northern Italy has shown that 26.5% of the patients that received an invitation from their physician for different methods of screening participated in colonoscopy^[53].

The common result of all studies is that there are no pathological findings in a majority of screening colonoscopies. The number of patients needed to screen in order to discover an adenoma is 9, for an advanced adenoma 23, and for a CRC 143^[41]. Further studies need to define low risk subgroups for colorectal neoplasia, which suit better for a non-invasive method of screening, and high-risk subgroups that necessarily need screening colonoscopy.

VIRTUAL COLONOSCOPY

A meta-analysis^[54] of virtual colonoscopy done by computer tomography showed an average sensitivity for large polyps of 85% (range: 48%-100%). In a recently published multicenter trial from the United States, the sensitivity for large adenomas and cancer was 90%^[55]. Only the data of a specialized center for radiology in the U.S. showed a comparable sensitivity of CT-Colography and colonoscopy^[56].

The dose of radiation of updated equipment is probably too low to cause long-term harm. Yet one has to consider the total dose of radiation to each patient. In Germany, the average dose of radiation is so high that CRC screening is unlikely to be introduced being performed by CT colography. Colography completed by MRI shows a comparable sensitivity than CT colography. In Germany, virtual colonoscopy is only recommended in studies thus far due to the lacking standardization of hardware and software

LATEST DEVELOPMENTS

In the past years, new technologies have been developed intending to abstain from sedation and to allow greater patient comfort. (1) Neo-Guide (Palo Alto, California) is a colonoscope built out of multiple flexible segments that adjust to the intestinal loops, preventing looping of the colonoscope. Biopsies can be taken, and the equipment can be reprocessed^[57]; (2) ColonoSight (San Jose, California) has a new infeed system with an inflatable mantle. The parts of the endoscope resting at the colonic walls are disposable, so there is no time-consuming disinfection in between examinations. LED-illumination makes glass-fibre optics and external light sources redundant. Biopsies can be taken^[58]; (3) Invendo (Weinheim, Germany) has a remote-controlled infeed with a new mantle technique. It is a disposable and biopsies can be taken^[59]; (4) CathCam consists of a disposable catheter with multiple lumina, a 3 mm camera, 6 illuminating diodes, and has a total diameter of 11 mm. CathCam is inserted in the caecum with a lumen detecting guide wire. The guide wire is inserted through a colonoscope that reaches the sigma^[60]; (5) Aeroscope (GI View, Israel) is a fully automated infeed system using the double balloon method. It runs with carbon dioxide pressure and reverses on its own once having reached the caecum. The system uses a 360-degree optic camera and a doctor does not need to be present during the examination^[61]. All new methods of colonoscopy have a high caecum rate of about 90% and sedation is usually not necessary; and (6) Pillcam Colon (Given Imaging, Israel). This newly developed colon capsule has a camera on both sides, taking two pictures per second. The images are recorded on an adaptor attached to the patient's belt and can be viewed *in vivo* on a real-time monitor. After excretion of the capsule, which happens within 10 h, the data can be conveyed on a computer that creates video sequences. The method is completely painless and




Figure 1 Future strategies of screening.

delivers pictures of the entire colon in good to excellent quality. The sensitivity for large polyps is about 70%^[62,63]. The system was approved in Germany in 2008 and may be used for CRC screening in selected persons who are able to drink 4 liters of colon lavage^[64].

PERSPECTIVES OF CRC SCREENING

For the foreseeable future, optical colonoscopy with the possibility of biopsy and polypectomy is likely to be the diagnostic test of choice in patients with positive screening tests. Colonoscopy should be the preferred screening method for high-risk groups (familial disposition, diabetes, adipositas, cigarette smoking *etc.*). The entire band of possible methods forms a portfolio for screening, so that each patient advised by his family physician can choose his favourite one (Figure 1).

REFERENCES

- 1 Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med* 1993; **328**: 1365-1371
- 2 Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet* 1996; **348**: 1472-1477
- 3 Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996; **348**: 1467-1471
- 4 Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassinville F, Bonithon-Kopp C. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. *Gastroenterology* 2004; **126**: 1674-1680
- 5 Sieg A, Scheida M, John MR, Hertel A, Schroter M, Luthgens K, Schmidt-Gayk H. Validity of new immunological human fecal hemoglobin and albumin tests in detecting colorectal neoplasms--an endoscopy-controlled study. *Z Gastroenterol* 1998; **36**: 485-490
- 6 Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Moslein G. [Comparison of different stool tests for the detection of cancer of the colon] *Dtsch Med Wochenschr* 2005; **130**: 872-877
- 7 Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance

- characteristics. *J Natl Cancer Inst* 2007; **99**: 1462-1470
- 8 **Morikawa T**, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. *Gastroenterology* 2005; **129**: 422-428
 - 9 **Guittet L**, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. *Gut* 2007; **56**: 210-214
 - 10 **Trojan J**, Povse N, Schroder O, Stein J. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. *Z Gastroenterol* 2002; **40**: 921-924
 - 11 **Hope RL**, Chu G, Hope AH, Newcombe RG, Gillespie PE, Williams SJ. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia. *Gut* 1996; **39**: 722-725
 - 12 **Wong BC**, Wong WM, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Lai KC, Hu WH, Chan CK, Lam SK. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. *Aliment Pharmacol Ther* 2003; **18**: 941-946
 - 13 **Levi Z**, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. *Aliment Pharmacol Ther* 2006; **23**: 1359-1364
 - 14 **Dancourt V**, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. *Eur J Cancer* 2008; **44**: 2254-2258
 - 15 **Hundt S**, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. *Ann Intern Med* 2009; **150**: 162-169
 - 16 **Hughes K**, Leggett B, Del Mar C, Croese J, Fairley S, Masson J, Aitken J, Clavarino A, Janda M, Stanton WR, Tong S, Newman B. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community. *Aust N Z J Public Health* 2005; **29**: 358-364
 - 17 **Fraser CG**, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. *Lancet Oncol* 2006; **7**: 127-131
 - 18 **Graser A**, Stieber P, Nagel D, Schafer C, Horst D, Becker CR, Nikolaou K, Lottes A, Geisbusch S, Kramer H, Wagner AC, Diepolder H, Schirra J, Roth HJ, Seidel D, Goke B, Reiser MF, Kolligs FT. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. *Gut* 2009; **58**: 241-248
 - 19 **Rozen P**, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. *Aliment Pharmacol Ther* 2009; **29**: 450-457
 - 20 **van Rossum LG**, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. *Gastroenterology* 2008; **135**: 82-90
 - 21 **Tannous B**, Lee-Lewandrowski E, Sharples C, Brugge W, Bigatello L, Thompson T, Benzer T, Lewandrowski K. Comparison of conventional guaiac to four immunochemical methods for fecal occult blood testing: implications for clinical practice in hospital and outpatient settings. *Clin Chim Acta* 2009; **400**: 120-122
 - 22 **Brown LF**, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. *Ann Clin Biochem* 2008; **45**: 604-605
 - 23 **Lüthgens K**, Maier A, Kampert I, Sieg A, Schmidt-Gayk H. Hemoglobin-Haptoglobin-Complex: A highly sensitive assay for the detection of fecal occult blood. *Clin Lab* 1998; **44**: 543-551
 - 24 **Sieg A**, Hertel A, John MR, Luthgens K, Schmidt-Gayk H. Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. *Eur J Cancer Prev* 1998; **7**: 279-285
 - 25 **Saito H**, Soma Y, Nakajima M, Koeda J, Kawaguchi H, Kakizaki R, Chiba R, Aisawa T, Munakata A. A case-control study evaluating occult blood screening for colorectal cancer with hemocult test and an immunochemical hemagglutination test. *Oncol Rep* 2000; **7**: 815-819
 - 26 **Morikawa T**, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, Shiratori Y. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. *Am J Gastroenterol* 2007; **102**: 2259-2264
 - 27 **Mulder SA**, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJ. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. *Eur J Gastroenterol Hepatol* 2007; **19**: 878-882
 - 28 **Shastri YM**, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rosch W, Mossner J, Stein JM. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. *Am J Gastroenterol* 2008; **103**: 1496-14504
 - 29 **Newcomb PA**, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. *J Natl Cancer Inst* 1992; **84**: 1572-1575
 - 30 **Selby JV**, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. *N Engl J Med* 1992; **326**: 653-657
 - 31 **Schoen RE**, Pinsky PF, Weissfeld JL, Bresalier RS, Church T, Prorok P, Gohagan JK. Results of repeat sigmoidoscopy 3 years after a negative examination. *JAMA* 2003; **290**: 41-48
 - 32 **Muller AD**, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. *Ann Intern Med* 1995; **123**: 904-910
 - 33 **Brenner H**, Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G. Long-lasting reduction of risk of colorectal cancer following screening endoscopy. *Br J Cancer* 2001; **85**: 972-976
 - 34 **Sieg A**, Theilmeier A. [Results of colonoscopy screening in 2005--an Internet-based documentation] *Dtsch Med Wochenschr* 2006; **131**: 379-383
 - 35 **Lieberman DA**, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. *N Engl J Med* 2001; **345**: 555-560
 - 36 **Lin OS**, Kozarek RA, Schembre DB, Ayub K, Gluck M, Drennan F, Soon MS, Rabeneck L. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. *JAMA* 2006; **295**: 2357-2365
 - 37 **Regula J**, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orłowska J, Nowacki MP, Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. *N Engl J Med* 2006; **355**: 1863-1872
 - 38 **Schoenfeld P**, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, Kikendall JW, Kim HM, Weiss DG, Emory T, Schatzkin A, Lieberman D. Colonoscopic screening of average-risk women for colorectal neoplasia. *N Engl J Med* 2005; **352**: 2061-2068
 - 39 **Strul H**, Kariv R, Leshno M, Halak A, Jakubowicz M, Santo M, Umansky M, Shirin H, Degani Y, Revivo M, Halpern Z, Arber N. The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 years. *Am J Gastroenterol* 2006; **101**: 255-262
 - 40 **Kim DH**, Lee SY, Choi KS, Lee HJ, Park SC, Kim J, Han CJ,

- Kim YC. The usefulness of colonoscopy as a screening test for detecting colorectal polyps. *Hepatogastroenterology* 2007; **54**: 2240-2242
- 41 **Kahi CJ**, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. *Gastroenterology* 2008; **135**: 380-399
- 42 **Huppe D**, Hartmann H, Felten G, Kemen M, Tannapfel A, Gillissen A, Katalinic A. [Effectiveness of screening colonoscopy in a community-based study] *Z Gastroenterol* 2008; **46**: 193-200
- 43 **Knöpnadel J**, Altenhofen L, Lichtner F, Brenner G. Früherkennung des Darmkrebses und möglicher Vorstufen. Wissenschaftliche Begleitung zur Einführung der Früherkennungskoloskopie in Deutschland im Auftrag der Spitzenverbände der Gesetzlichen Krankenkassen und der Kassenärztlichen Bundesvereinigung. Auswertungen der Dokumentationen zur Früherkennungskoloskopie Berichtszeitraum 2003 (1. Quartal 2003 - 4. Quartal 2003). Köln: Deutscher Ärzte-Verlag 2005 (Wissenschaftliche Reihe des Zentralinstitutes, Band 59)
- 44 **Sieg A**, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. *Gastrointest Endosc* 2001; **53**: 620-627
- 45 **Hixson LJ**, Fennerty MB, Sampliner RE, Garewal HS. Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps. *Gastrointest Endosc* 1991; **37**: 125-127
- 46 **Rex DK**, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. *Gastroenterology* 1997; **112**: 24-28
- 47 **Bensen S**, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. *Am J Gastroenterol* 1999; **94**: 194-199
- 48 **Shehadeh I**, Rebala S, Kumar R, Markert RJ, Barde C, Gopalswamy N. Retrospective analysis of missed advanced adenomas on surveillance colonoscopy. *Am J Gastroenterol* 2002; **97**: 1143-1147
- 49 **van Rijn JC**, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol* 2006; **101**: 343-350
- 50 **Froehlich F**, Wietlisbach V, Gonvers JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. *Gastrointest Endosc* 2005; **61**: 378-384
- 51 **Barclay RL**, Vicari JJ, Greenlaw RL. Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy. *Clin Gastroenterol Hepatol* 2008; **6**: 1091-1098
- 52 **Sieg A**, Brenner H. Cost-saving analysis of screening colonoscopy in Germany. *Z Gastroenterol* 2007; **45**: 945-951
- 53 **Segnan N**, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. *Gastroenterology* 2007; **132**: 2304-2312
- 54 **Mulhall BP**, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. *Ann Intern Med* 2005; **142**: 635-650
- 55 **Johnson CD**, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ. Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med* 2008; **359**: 1207-1217
- 56 **Pickhardt PJ**, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, Wong RK, Nugent PA, Mysliwiec PA, Schindler WR. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N Engl J Med* 2003; **349**: 2191-2200
- 57 **Eickhoff A**, van Dam J, Jakobs R, Kudis V, Hartmann D, Damian U, Weickert U, Schilling D, Riemann JF. Computer-assisted colonoscopy (the NeoGuide Endoscopy System): results of the first human clinical trial ("PACE study"). *Am J Gastroenterol* 2007; **102**: 261-266
- 58 **Shike M**, Fireman Z, Eliakim R, Segol O, Sloyer A, Cohen LB, Goldfarb-Albak S, Repici A. Sightline Colonosight system for a disposable, power-assisted, non-fiber-optic colonoscopy (with video). *Gastrointest Endosc* 2008; **68**: 701-710
- 59 **Rosch T**, Adler A, Pohl H, Wettschureck E, Koch M, Wiedenmann B, Hoepffner N. A motor-driven single-use colonoscope controlled with a hand-held device: a feasibility study in volunteers. *Gastrointest Endosc* 2008; **67**: 1139-1146
- 60 **Fritscher-Ravens A**, Fox S, Swain CP, Milla P, Long G. CathCam guide wire-directed colonoscopy: first pilot study in patients with a previous incomplete colonoscopy. *Endoscopy* 2006; **38**: 209-213
- 61 **Vucelic B**, Rex D, Pulanic R, Pfefer J, Hrstic I, Levin B, Halpern Z, Arber N. The aer-o-scope: proof of concept of a pneumatic, skill-independent, self-propelling, self-navigating colonoscope. *Gastroenterology* 2006; **130**: 672-677
- 62 **Eliakim R**, Fireman Z, Gralnek IM, Yassin K, Waterman M, Kopelman Y, Lachter J, Koslowsky B, Adler SN. Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study. *Endoscopy* 2006; **38**: 963-970
- 63 **Schoofs N**, Deviere J, Van Gossum A. PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. *Endoscopy* 2006; **38**: 971-977
- 64 **Sieg A**, Friedrich K, Sieg U. Is PillCam COLON capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice. *Am J Gastroenterol* 2009; **104**: 848-854

S- Editor Li JL L- Editor Alpini GD E- Editor Ma WH